ArticleScientific reports2026
Potential utility of postmortem CT-based classification as a practical pre-autopsy assessment tool for hepatic steatosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to establish postmortem computed tomography (PMCT)-specific Hounsfield unit (HU) criteria and developed an HU-based assessment tool for pre-autopsy triage of hepatic steatosis. Overall, 166 deceased individuals underwent whole-body PMCT followed by autopsy with liver histopathology. Hepatic attenuation was measured as a volumetric mean HU of the entire liver and as a four-point mean HU. No significant difference was noted between the volumetric and four-point mean HU (p = 0.183). However, the four-point mean HU differed significantly across histological steatosis grades (p < 0.001) and decreased with increasing severity, although the difference between mild and moderate steatosis was non-significant (p = 0.981). Receiver operating characteristic analysis indicated an optimal cutoff of 42.59 HU (sensitivity 60.7%, specificity 86.1%), from which three HU-based categories were defined (≥ 44.5 HU: normal; 42.0-44.4 HU: borderline; <42.0 HU: suspected steatosis). In the validation cohort (n = 104), the tool achieved an accuracy of 0.865, sensitivity of 0.756, specificity of 0.949, precision of 0.919, and F1-score of 0.829. This three-category PMCT HU-based classification system provides a practical tool for the triage of hepatic steatosis. The high specificity and precision support its use as a rule-in aid to prioritize suspected steatosis cases and improve autopsy workflow efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.